johnson & johnson - Search News

Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

AOL · 11h

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share.

Business Insider · 16h

Johnson & Johnson Q4 Profit Decreases, But Beats Estimates

Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The

The Motley Fool on MSN · 17h

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript

Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Seeking Alpha · 12h

Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.

Zacks.com on MSN · 16h

Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.

FDA approves Johnson & Johnson’s nasal spray for depression

Fortune on MSN · 3h

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

U.S. News & World Report · 11h

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,

Popular Science · 12h

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Ben Johnson takes a jab at Matt LaFleur

USA TODAY Touchdown Wire o… · 5h

Ben Johnson praises Lions players, organization in first press conference with Bears

Former Detroit Lions offensive coordinator Ben Johnson officially joined the division rival Chicago Bears on Tuesday, and the team introduced him as their new head coach in a news conference on Wed

ESPN · 6h

Ben Johnson takes a jab at Matt LaFleur during introductory news conference

Bears head coach Ben Johnson makes a joke about beating Packers coach Matt LaFleur twice a season.

Yahoo! Sports · 9h

'I kinda enjoyed beating Matt LaFleur': Takeaways from Ben Johnson's Chicago Bears press conference

Here are our takeaways from Ben Johnson's introductory press conference as the Chicago Bears' next head coach.

15h

Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond

Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...

MassDevice16h

Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

12hon MSN

Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

13h

Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

23h

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone ...

TipRanks on MSN3d

Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards

Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...

1don MSN

Jim Cramer on Johnson & Johnson (JNJ): ‘Make Good Money Just By Reinvesting Their Juicy Dividends’

We recently published an article titled Jim Cramer Discussed 9 Stocks for This Week’s Game Plan. In this article, we are ...

Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?

Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Johnson & Johnson Q4 Profit Decreases

FDA approves Johnson & Johnson’s nasal spray for depression

Ben Johnson takes a jab at Matt LaFleur

Related topics